217 filings
Page 3 of 11
8-K
lihtq2t
13 Dec 22
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
8:07am
8-K
fkj2ads lk
8 Dec 22
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
8:14am
8-K
xb7zlb0oh4v an1q
29 Nov 22
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
8:10am
8-K
4cky1h 8nyzkra4nlqpa
10 Nov 22
Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update
4:24pm
8-K
ywnlfmahocd222t8t
7 Nov 22
Termination of a Material Definitive Agreement
4:34pm
8-K
3xke48
20 Oct 22
Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential
8:34am
8-K
73qpm
30 Sep 22
Departure of Directors or Certain Officers
8:12am
S-8
pjr5kgxyzo7ewvue
12 Aug 22
Registration of securities for employees
4:01pm
8-K
84v7ps
10 Aug 22
Eyenovia Reports Second Quarter 2022 Financial Results
4:55pm
8-K
0fak bb9ie2egi
27 Jul 22
Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member
9:05am
8-K
hvlkhybn9fr8rs4x9h
7 Jul 22
Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors
9:08am
8-K
el0zes3aqgpkemafkv
17 Jun 22
Departure of Directors or Certain Officers
6:30am
8-K
kk7qs
7 Jun 22
Eyenovia Announces Planned Chief Executive Officer Transition
8:23am
8-K
xhtuimkzu w6x
12 May 22
Eyenovia Reports First Quarter 2022 Financial Results
5:21pm
8-K
fo8 i6tpwa
12 May 22
Entry into a Material Definitive Agreement
5:20pm
DEFA14A
w7g7qlzq
2 May 22
Additional proxy soliciting materials
8:53am